← All trials
NCT05550402
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2023
- Primary completion
- Jun 1, 2023
- Completion date
- Jun 30, 2023
- First posted
- Sep 22, 2022
- Last posted
- Sep 22, 2022
- Enrollment
- 30
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Hat Yai Medical Education CenterLead sponsor
- Hat Yai Medical Education CenterReponsible party - principal investigator
- Hat Yai Medical Education CenterSponsor investigator
- Hatyai HospitalOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.